Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with a documented relapsed or refractory synovial sarcoma after standard chemotherapy~2. Patients ≥18 years of age at the time of obtaining informed consent~3. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1~4. Patients with measurable lesion~5. Patients not received any anti-malignancy agent or specified surgical intervention within 28 days or specified radiotherapy within 14 days prior to study registration.~6. Patients without any clinically significant laboratory abnormality.~7. Patients with adequate heart function as measured by echocardiography or multiple gated acquisition scan (MUGA).~8. Patients with adequate pulmonary function as measured by pulmonary function tests.~9. Patients who are either not of childbearing potential or who agree to use a contraception method during the study and for 12 months after the last dose of study drug~10. Patients must be able to understand and be willing to sign a written informed consent~Exclusion Criteria:~1. Patients with documented concurrent malignancy.~2. Patients with brain metastasis with clinical symptoms.~3. Patients with any infection requiring systemic treatment.~4. Patients with lung inflammation or pulmonary fibrosis.~5. Patients with a known history of hypersensitivities to antibody agents or serum albumin agents.~6. Patients with a known history of autoimmune diseases.~7. Patients with myocardial infarction (MI) within 6 months prior to study registration.~8. Patients with uncontrolled diseases.~9. Patients with any disease requiring continuous systemic administration of steroids or immunosuppressants.~10. Patients with evidence of active HBV, HCV or HIV infection.~11. Pregnant or breastfeeding female patients, or female patients with suspected pregnancy.~12. Patients who are participating any other investigational treatments during the study.~13. Patients with psychiatric disorders and is considered to have difficulty to study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Study Arm, no competitor (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).